AC
Ascend Capital Portfolio holdings
AUM
$1.99B
1-Year Return
10.47%
This Quarter Return
+3.05%
1 Year Return
+10.47%
3 Year Return
+55.79%
5 Year Return
+85.99%
10 Year Return
–
AUM
$2.9B
AUM Growth
+$318M
(+12%)
Cap. Flow
+$152M
Cap. Flow
% of AUM
5.25%
Top 10 Holdings %
Top 10 Hldgs %
24.95%
Holding
239
New
83
Increased
29
Reduced
44
Closed
77
Top Buys
| 1 |
Danaher
DHR
|
$90.4M |
| 2 |
FedEx
FDX
|
$79M |
| 3 |
HUB.B
HUBBELL INC CL-B
HUB.B
|
$78.7M |
| 4 |
Baxter International
BAX
|
$74M |
| 5 |
PPG Industries
PPG
|
$63.5M |
Top Sells
| 1 |
ANDV
Andeavor
ANDV
|
$54.1M |
| 2 |
Huntsman Corp
HUN
|
$52.3M |
| 3 |
AGN
ALLERGAN INC
AGN
|
$50.5M |
| 4 |
Gilead Sciences
GILD
|
$48.4M |
| 5 |
Garmin
GRMN
|
$39.9M |
Sector Composition
| 1 | Technology | 19.08% |
| 2 | Healthcare | 14.4% |
| 3 | Consumer Discretionary | 11.4% |
| 4 | Industrials | 10.62% |
| 5 | Financials | 8.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
ProQR Therapeutics
PRQR
$252M
| $656K | 0.02% |
30,000
-60,000
| -67% | -$1.31M |
|
|
SC
152
DELISTED
SANTANDER CONSUMER USA HOLDINGS INC
SC
| $582K | 0.02% |
25,099
-401,590
| -94% | -$9.31M |
|
|
BLUE
153
DELISTED
bluebird bio
BLUE
| $555K | 0.02% |
+355
| New | +$555K |
|
154
Arbutus Biopharma
ABUS
$753M
| $349K | 0.01% |
+20,000
| New | +$349K |
|
|
RPRX
155
DELISTED
Repros Therapeutics Inc.
RPRX
| $343K | 0.01% |
+40,000
| New | +$343K |
|
156
Vivani Medical
VANI
$81.2M
| $128K | ﹤0.01% |
+417
| New | +$128K |
|
157
Advance Auto Parts
AAP
$3.6B
| – | – |
-152,067
| Closed | -$24.2M |
|
158
Apple
AAPL
$3.56T
| – | – |
-403,152
| Closed | -$11.1M |
|
159
Alto Ingredients
ALTO
$89M
| – | – |
-572,021
| Closed | -$5.91M |
|
160
Aon
AON
$80.5B
| – | – |
-162,943
| Closed | -$15.5M |
|
|
AVDL
161
Avadel Pharmaceuticals
AVDL
$1.46B
| – | – |
-21,497
| Closed | -$368K |
|
162
Avnet
AVT
$4.47B
| – | – |
-224,799
| Closed | -$9.67M |
|
163
American Express
AXP
$230B
| – | – |
-115,154
| Closed | -$10.7M |
|
164
AstraZeneca
AZN
$254B
| – | – |
-403,130
| Closed | -$14.2M |
|
165
Biogen
BIIB
$20.5B
| – | – |
-40,313
| Closed | -$13.7M |
|
166
Bank of New York Mellon
BK
$74.4B
| – | – |
-145,581
| Closed | -$5.91M |
|
167
BioMarin Pharmaceuticals
BMRN
$10.9B
| – | – |
-20,000
| Closed | -$1.81M |
|
168
Coca-Cola Europacific Partners
CCEP
$39.7B
| – | – |
-718,970
| Closed | -$31.8M |
|
169
Crown Holdings
CCK
$10.7B
| – | – |
-86,996
| Closed | -$4.43M |
|
170
CF Industries
CF
$13.6B
| – | – |
-100,000
| Closed | -$5.45M |
|
171
Copa Holdings
CPA
$4.86B
| – | – |
-18,969
| Closed | -$1.97M |
|
172
Carlisle Companies
CSL
$16.8B
| – | – |
-56,281
| Closed | -$5.08M |
|
173
Constellium
CSTM
$1.95B
| – | – |
-301,281
| Closed | -$4.95M |
|
174
Darden Restaurants
DRI
$24.5B
| – | – |
-281,836
| Closed | -$14.8M |
|
175
EOG Resources
EOG
$66.4B
| – | – |
-100,786
| Closed | -$9.28M |
|